ArticleEuropean journal of medical research2025
Tanshinone IIA induces ferroptosis in colorectal cancer cells through the suppression of SLC7A11 expression via the PI3K/AKT/mTOR pathway.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- A network toxicology and machine learning approach to uncover the molecular machinery of bisphenol A-induced colorectal cancer.Scientific reports · 2026Article
- Tanshinone IIA suppresses cancer metastasis by modulating tumor cell-platelet-endothelial cell interactions.Oncology letters · 2026Article
- Targeting SLC7A11 with Chinese Medicine for Tumor Ferroptosis Induction: From Molecular Mechanisms to Novel Precision Therapeutic Strategies.Chinese journal of integrative medicine · 2026Review
- Targeting lung cancer with tanshinones: Current mechanistic evidence and emerging opportunities (Review).Oncology reports · 2026Review
- Natural Products in Cancer Prevention and Therapy: Current Challenges and Future Directions.MedComm · 2026Review
- Cancer stem cell-driven drug resistance in colorectal carcinoma: molecular aspects and therapeutic potentials.Molecular cancer · 2026Review
- Biomimetic M1 Macrophage Membrane-Camouflaged Nanoplatform Remodels Tumor Microenvironment for Enhanced Antitumor Immunity.International journal of nanomedicine · 2026Article
- Tanshinone IIA inhibits malignant progression in a spontaneous breast cancer mouse model by attenuating tissue factor-mediated angiogenesis.Frontiers in pharmacology · 2026Article
- Investigating the Development of Colorectal Cancer Based on Spatial Transcriptomics.International journal of molecular sciences · 2025Article
- Ferroptosis: Mechanisms, Comparison with Cuproptosis and Emerging Horizons in Therapeutics.Oncology research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is a malignant tumor of the digestive system with high incidence rate and mortality. Tanshinone IIA (Tan IIA) plays an anti-cancer role in a variety of cancer cells. Here, we aimed to elucidate the therapeutic effects and potential mechanism of Tan IIA in CRC.
methodsOUMS23 cells were treated with 0, 5, 10, or 20 μM Tan IIA, and CRC mice were exposed to 20 μM Tan IIA + SLC7A11 plasmid. Edu and flow cytometry analyses were performed to assay cell proliferation and apoptosis, respectively. An Iron Assay Kit was used for determining total iron and Fe
resultsTan IIA suppressed CRC proliferation in a dose-dependent manner. Moreover, Tan IIA inhibited SLC7A11 expression in OUMS23 cells and tumor tissues. Functional assays showed that Tan IIA induces CRC apoptosis, ferroptosis, and ROS release in intracellular and tumor tissues, while SLC7A11 plasmid transfection reverses these effects. Furthermore, SLC7A11 plasmid reversed the effects of Tan IIA on tumor volume and weight in CRC subcutaneous tumors. Further experiments revealed that SLC7A11 plasmid abolished the effects of Tan IIA on the PI3K/AKT/mTOR pathway, as confirmed by increased phospho (p)-AKT and p-mTOR expression, as well as increased p-AKT/AKT and p-mTOR/ mTOR ratios.
conclusionTan IIA induces ferroptosis in CRC by suppressing SLC7A11 expression through the PI3K/AKT/mTOR pathway. Therefore, Tan IIA may be an effective therapeutic agent in the treatment of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.